4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Clinical development of a dendritic-cell vaccine therapy for acute myeloid leukaemia (AML-VACCiN)
Date du début: 1 janv. 2016, Date de fin: 31 mars 2020,
Eradicating minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML) is an area of high unmet medical need. AML is a deadly rare disease that affects both children and adults. Approximately 45% of younger AML patients who are treated will be cured, and in older patients (>60 years of age), 85% will relapse and die within 2 years.Immunotherapy has great potential for treating M ...
Voir le projet
12
Participants partenaires
TERMINÉ
Cancer Vaccine development for Hepatocellular Carcinoma (HepaVac)
Date du début: 1 sept. 2013, Date de fin: 31 août 2018,
"Hepatocellular carcinoma (HCC) is the most common primary liver cancer and accounts for about 6% of all new cancer cases worldwide. Given the lack of available effective treatments, the overall prognosis for HCC patients is poor, with a dismal 5-year survival of 5-6%. The main goal of this proposal is to develop a therapeutic cancer vaccine aiming at improving clinical outcome in early-stage HCC ...
Voir le projet
10
Participants partenaires
TERMINÉ
Glioma Actively Personalized Vaccine Consortium (GAPVAC)
Date du début: 1 nov. 2012, Date de fin: 31 janv. 2017,
"Glioblastoma (GBM) is a rare (2-3 incidences in 100,000) and fatal disease. Each year, approximately 13,000 new cases of GBM are diagnosed in Europe. The 5-year survival rate of this highly aggressive tumor entity under conventional therapy is less than 6%. Currently available therapeutic options neglect the individuality of each patients’ disease and only temporarily influence tumor progression ...
Voir le projet
13
Participants partenaires
TERMINÉ
IMmune MOdulating strategies for treatment of MErkel cell Carcinoma (IMMOMEC)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2016,
"Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer of the skin associated with the recently discovered, common Merkel cell polyomavirus (MCV). With an incidence of 0.44 per 100,000 MCC is a very rare cancer. Notably, however, although MCC is 40 times less common than malignant melanoma, MCC has a dramatically higher mortality rate than melanoma rendering MCC to ...
Voir le projet